ABL Diagnostics (XPAR:ABLD) EPS without NRI: €0.06 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ABLD ABL Diagnostics XPAR:ABLD
50 GF Score
Price €2.34
GF Value €7.85
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is ABL Diagnostics EPS without NRI?

ABL Diagnostics XPAR:ABLD +0.86% 50 EPS without NRI is €0.06 as of Dec. 2025. GuruFocus rates XPAR:ABLD with a GF Score™ of 50/100 and a GF Value™ of €7.85 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 510 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 52.55% on this metric.

ABL Diagnostics's earnings per share without non-recurring items for the six months ended in Dec. 2025 was €0.05. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06.

During the past 12 months, ABL Diagnostics's average earnings per share (NRI) Growth Rate was 342.90% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 13.00% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for ABL Diagnostics's EPS without NRI or its related term are showing as below:

XPAR:ABLD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -30.3   Med: 13   Max: 32.4
Current: 13

During the past 13 years, ABL Diagnostics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 32.40% per year. The lowest was -30.30% per year. And the median was 13.00% per year.

XPAR:ABLD's 3-Year EPS without NRI Growth Rate is ranked better than
52.55% of 510 companies
in the Healthcare Providers & Services industry
Industry Median: 11.55 vs XPAR:ABLD: 13.00

ABL Diagnostics's EPS (Diluted) for the six months ended in Dec. 2025 was €0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06.

ABL Diagnostics's EPS (Basic) for the six months ended in Dec. 2025 was €0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.06.


ABL Diagnostics  (XPAR:ABLD) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ABL Diagnostics EPS without NRI Related Terms


ABL Diagnostics EPS without NRI Historical Data

* Premium members only.

The historical data trend for ABL Diagnostics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABL Diagnostics EPS without NRI Chart

ABL Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 0.04 0.00 0.01 0.06

ABL Diagnostics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.01 0.02 0.05

XPAR:ABLD vs VEEV, BTSG, TEM: EPS without NRI Comparison

For the Health Information Services subindustry, ABL Diagnostics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABL Diagnostics PE Ratio without NRI vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's PE Ratio without NRI falls into.


XPAR:ABLD
50GF Score
ABL Diagnostics XPAR:ABLD
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ABL Diagnostics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €0.06 mean?
ABL Diagnostics (XPAR:ABLD) has a EPS without NRI of €0.06 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ABL Diagnostics and its competitors. According to the industry distribution chart, ABL Diagnostics ranks #242 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 47.5%.
Is ABL Diagnostics' EPS without NRI too high?
ABL Diagnostics' current EPS without NRI is €0.06. Based on the distribution chart, ABL Diagnostics ranks #242 out of 510 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' EPS without NRI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #242 out of 510 companies for EPS without NRI. This puts ABL Diagnostics in the upper half of its industry. The industry median EPS without NRI is 11.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.55, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current EPS without NRI is €0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.85, compared to a current price of €2.34 — trading 70.2% below its estimated fair value. The current EPS without NRI is €0.06. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current EPS without NRI is €0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?

Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued. The current stock price of €2.34 is trading 70.2% below its estimated GF Value™ of €7.85. GuruFocus considers ABL Diagnostics to be Significantly Undervalued.

Key valuation signals for XPAR:ABLD:

  • EPS without NRI: €0.06
  • GF Value™: €7.85 vs. price of €2.34 (70.2% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ABL Diagnostics Business Description

Other Exchanges 9BK0:Germany
Address 72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score

Get the complete analysis for XPAR:ABLD

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.34
Price
€7.85
GF Value